Abstract
Introduction: Primary and secondary prevention of cardiovascular Disease (CVD) are major concerns and priorities. The best tools that we actually have to prevent CVD are the biomarkers. Numerous studies have shown that the presentation of cardiac disease in women is quite different from the presentation in men. Thus, one question arises “Are there any differences in biomarkers as well?” The answer to this question could open new avenues for a tailored management of cardiac diseases. Method and Results: We searched the PubMed and Medline databases for articles comparing differences between the 2 genders in terms of biomarker expression. Keywords used included “Cardiovascular biomarkers sex differences”. We reviewed the role of different biomarkers in the 2 genders in relation to cardiac events. Conclusions: Differences of expressions in biomarker levels were found between the 2 genders. Further investigation should be promoted.
Keywords: Cardiovascular biomarkers, gender differences.
Current Vascular Pharmacology
Title:Sex Differences in Biomarkers for Predicting Cardiovascular and Coronary Events
Volume: 11 Issue: 5
Author(s): Erjon Agushi, Borejda Xhyheri and Raffaele Bugiardini
Affiliation:
Keywords: Cardiovascular biomarkers, gender differences.
Abstract: Introduction: Primary and secondary prevention of cardiovascular Disease (CVD) are major concerns and priorities. The best tools that we actually have to prevent CVD are the biomarkers. Numerous studies have shown that the presentation of cardiac disease in women is quite different from the presentation in men. Thus, one question arises “Are there any differences in biomarkers as well?” The answer to this question could open new avenues for a tailored management of cardiac diseases. Method and Results: We searched the PubMed and Medline databases for articles comparing differences between the 2 genders in terms of biomarker expression. Keywords used included “Cardiovascular biomarkers sex differences”. We reviewed the role of different biomarkers in the 2 genders in relation to cardiac events. Conclusions: Differences of expressions in biomarker levels were found between the 2 genders. Further investigation should be promoted.
Export Options
About this article
Cite this article as:
Agushi Erjon, Xhyheri Borejda and Bugiardini Raffaele, Sex Differences in Biomarkers for Predicting Cardiovascular and Coronary Events, Current Vascular Pharmacology 2013; 11 (5) . https://dx.doi.org/10.2174/1570161111311050017
DOI https://dx.doi.org/10.2174/1570161111311050017 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ammonium Activates Ouabain-Activated Signalling Pathway in Astrocytes: Therapeutic Potential of Ouabain Antagonist
Current Neuropharmacology Endotherapia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Refined Echocardiographic Assessment and Contemporary Medical Treatment of Obstructive Hypertrophic Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets Role of Oxidative-Nitrosative Stress and Downstream Pathways in Various Forms of Cardiomyopathy and Heart Failure
Current Vascular Pharmacology Nanoparticles: A Neurotoxicological Perspective
CNS & Neurological Disorders - Drug Targets Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets Exercise and Stevia Rebaudiana (R) Extracts Attenuate Diabetic Cardiomyopathy in Type 2 Diabetic Rats: Possible Underlying Mechanisms
Endocrine, Metabolic & Immune Disorders - Drug Targets HspB5/αB-Crystallin: Properties and Current Progress in Neuropathy
Current Neurovascular Research Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry Regulation of Oxidative Stress and Cardioprotection in Diabetes Mellitus
Current Cardiology Reviews The Meaning of Different Forms of Structural Myocardial Injury, Immune Response and Timing of Infarct Necrosis and Cardiac Repair
Current Vascular Pharmacology Fibrosis as a Therapeutic Target Post-Myocardial Infarction
Current Pharmaceutical Design Clearing the Brains Cobwebs: The Role of Autophagy in Neuroprotection
Current Neuropharmacology Rational Autologous Cell Sources For Therapy of Heart Failure - Vehicles and Targets For Gene and RNA Therapies
Current Gene Therapy Mitochondrial Alterations and Neuropsychiatric Disorders
Current Medicinal Chemistry Clozapine Safety, 35 Years Later
Current Drug Safety Abnormal Insulin Signaling: Early Detection of Silent Coronary Artery Disease-Erectile Dysfunction?
Current Pharmaceutical Design Markers of Atherosclerotic Disease: What do they Mean? Current Opinion and Future Trends
Current Pharmaceutical Design The CD4C/HIVNef Transgenic Model of AIDS
Current HIV Research Mitochondria-Targeted Drugs
Current Molecular Pharmacology